ArticleFrontiers in oncology2026
M2 macrophage-derived exosomes and miR-132-3p promote gastric cancer cell aggressiveness and attenuate ferroptosis-related changes.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to explore the correlation between the ability of M2-type tumor-correlated macrophage-derived exosomes (EXOs) to trigger the aggressiveness of gastric cancer (GC) cells and the miR-132-3p expression. Methods: EXOs were isolated from the conditioned media of M0 and M2 macrophages and characterized by transmission electron microscopy and Western blotting. miR-132-3p expression was determined by qRT-PCR. HGC-27 cells were divided into the control, miR-132-3p mimic, miR-132-3p inhibitor, M0-EXO, and M2-EXO groups. Cell viability, proliferation, migration, and invasion were assessed using CCK-8, EdU, and Transwell assays. Intracellular GSH, SOD, MDA, and iron levels were measured using colorimetric assays. FTH1, LIFR, and GPX4 expressions were detected by Western blotting. RNA sequencing and bioinformatics analyses were performed to investigate miR-132-3p-mediated transcriptional changes and ferroptosis-related pathways in HGC-27 cells. Results: miR-132-3p was significantly enriched in M2 macrophage-derived exosomes and was highly expressed in GC, with its expression associated with tumor stage, grade, and other clinicopathological features. M2-Exo treatment significantly increased miR-132-3p levels in HGC-27 cells. Both miR-132-3p overexpression and M2-Exo treatment enhanced the proliferation, migration, and invasion of HGC-27 cells, and were accompanied by reduced intracellular iron and MDA levels, increased GSH content and SOD activity, upregulated FTH1 and GPX4 expression, and decreased LIFR expression. In contrast, miR-132-3p inhibition produced largely opposite effects. RNA-seq identified 275 differentially expressed genes following miR-132-3p overexpression, including 216 upregulated and 59 downregulated genes. GO and KEGG analyses revealed significant alterations in biological processes and pathways related to oxygen transport, ATP synthesis, oxidative phosphorylation, thermogenesis, spliceosome function, and endoplasmic reticulum protein processing. Integration of the RNA-seq-derived DEGs with FerrDb identified 12 ferroptosis-related DEGs, including 11 upregulated genes and 1 downregulated gene. qRT-PCR validation showed expression patterns broadly consistent with the RNA-seq results. Conclusion: miR-132-3p expression in the EXOs of M2-type macrophages was significantly elevated, and the EXOs of M2-type macrophages significantly triggered the aggressiveness of GC cells and inhibited ferroptosis in GC cells, which may be resulting from the prevention of ferroptosis through the transport of miR-132-3p; nevertheless, the specific mechanism of action needs to be further elucidated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.